CLVS

Clovis Oncology, Inc. Press Releases

$65.39
*  
3.055
4.46%
Get CLVS Alerts
*Delayed - data as of Jan. 28, 2015  -  Find a broker to begin trading CLVS now
Exchange: NASDAQ
Industry: Health Care
Community Rating:
View:    CLVS Pre-Market
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks
Viewing
Filtered By
Ordered By
Clovis Oncology to Present at the 33rd Annual J.P. Morgan Healthcare Conference
1/5/2015 6:30:00 PM - Business Wire
▲16.79 % Price Change since this news event. The Volume Ratio is 1.37.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Foundation Medicine’s Novel Companion Diagnostic Test, Developed in Collaboration with Clovis Oncology, Identifies Expanded Subgroup of Cancer Patients with the Potential to Respond to Clovis Oncology’s PARP inhibitor, Rucaparib
11/19/2014 6:05:00 PM - Business Wire


Initial Data from Ongoing Phase 2 ARIEL2 Study of Rucaparib in Ovarian Cancer Demonstrate Encouraging Clinical Activity and Safety in both BRCA Mutant and BRCAness Patients
11/19/2014 6:01:00 PM - Business Wire


Interim Data from Rociletinib (CO-1686) Phase 1/2 Study Shows Compelling and Durable Clinical Activity and Progression-free Survival (PFS) in Patients with EGFR-Mutant Non-small Cell Lung Cancer (NSCLC)
11/18/2014 6:36:00 PM - Business Wire


Clovis Oncology Enters into Oncology Clinical Trial Collaboration with GlaxoSmithKline
11/17/2014 5:00:00 PM - Business Wire


Clovis Oncology Announces First Patient Enrolled in TIGER-1 Study
11/12/2014 5:28:00 PM - Business Wire
▲11.89 % Price Change since this news event. The Volume Ratio is 0.88.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Clovis Oncology Announces Third Quarter 2014 Operating Results
11/6/2014 4:01:00 PM - Business Wire
▲11.64 % Price Change since this news event. The Volume Ratio is 1.23.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Clovis Oncology to Present at the 2014 Credit Suisse Healthcare Conference
11/4/2014 4:05:00 PM - Business Wire
▲10.92 % Price Change since this news event. The Volume Ratio is 0.87.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Arsenal Energy Inc. Announces 2014 Third Quarter Results and Declares Quarterly Dividend
11/4/2014 4:05:00 PM - Market Wire